XML 22 R13.htm IDEA: XBRL DOCUMENT
v3.21.2

Disaggregation of Revenues and Concentration Risk | 9 Months Ended
--- | ---
Sep. 30, 2021
Disaggregation Of Revenues And Concentration Risk |
Disaggregation of Revenues and Concentration Risk | 7. Disaggregation of Revenues and Concentration Risk The following table presents the percentage of consolidated revenues generated by unaffiliated customers that individually represent greater than ten percent of consolidated revenues: Schedule of Consolidated Revenues Generated by Unaffiliated Customers
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Medicare for DetermaRx |  |  | 23 | % |  |  | 35 | % |  |  | 23 | % |  |  | 27 | %
Medicare Advantage for DetermaRx |  |  | 16 | % |  |  | 0* |  |  |  | 17 | % |  |  | 0* |
Pharma services Company A |  |  | 0* |  |  |  | 0* |  |  |  | 0* |  |  |  | 21 | %
Pharma services Company B |  |  | 0* |  |  |  | 28 | % |  |  | 0* |  |  |  | 22 | %
Pharma services Other |  |  | 26 | % |  |  | 26 | % |  |  | 11 | % |  |  | 27 | %
Licensing - Company D |  |  | 0* |  |  |  | 0* |  |  |  | 25 | % |  |  | 0* |
Licensing - Company B |  |  | 26 | % |  |  | 0* |  |  |  | 12 | % |  |  | 0* |
* | Less than 10%
The following table presents the percentage of consolidated revenues by products or services classes: Schedule of Consolidated Revenues Attributable to Products or Services
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
DetermaRx |  |  | 41 | % |  |  | 37 | % |  |  | 40 | % |  |  | 31 | %
Pharma Services |  |  | 29 | % |  |  | 63 | % |  |  | 23 | % |  |  | 69 | %
Licensing |  |  | 30 | % |  |  | - |  |  |  | 37 | % |  |  | - |
Total |  |  | 100 | % |  |  | 100 | % |  |  | 100 | % |  |  | 100 | %
The following table presents the percentage of consolidated revenues attributable to geographical locations: Schedule of Percentage of Consolidated Revenues Attributable to Geographical Locations
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
United States |  |  | 61 | % |  |  | 63 | % |  |  | 41 | % |  |  | 56 | %
Outside of the United States – Pharma Services |  |  | 9 | % |  |  | 37 | % |  |  | 22 | % |  |  | 44 | %
Outside of the United States – Licensing |  |  | 30 | % |  |  | - |  |  |  | 37 | % |  |  | - |
Total |  |  | 100 | % |  |  | 100 | % |  |  | 100 | % |  |  | 100 | %
The following table presents Oncocyte’s total accounts receivable from third-party payers and other customers at September 30, 2021 and December 31, 2021. Schedule of Accounts Receivable from Third Party and Other Customers
|  | September 30, 2021 |  |  | December 31, 2020 |
Medicare for DetermaRx™ |  | $ | 148 |  |  | $ | 91 |
Medicare Advantage for DetermaRx™ |  |  | 597 |  |  |  | - |
Pharma Services and other |  |  | 287 |  |  |  | 112 |
Total |  | $ | 1,032 |  |  | $ | 203 |
As of December 31, 2020, our accounts receivable were $0.2 million. During the nine months ending September 30, 2021, our accounts receivable increased by $4.1 million for revenues recognized, offset by cash collected of approximately $2.7 million and $0.5 million of deferred revenue recognized (see Notes 2 and 3). The following table presents accounts receivable, as a percentage of total consolidated accounts receivables, from third-party payers and other customers that provided in excess of 10% of Oncocyte’s total accounts receivable. Schedule of Percentage of Total Consolidated Accounts Receivables
|  | September 30, 2021 |  |  | December 31, 2020 |
Medicare for DetermaRx™ |  |  | 14 | % |  |  | 45 | %
Medicare Advantage for DetermaRx™ |  |  | 58 | % |  |  | * |
Pharma Services Company A |  |  | * |  |  |  | 35 | %

X
- Definition Disaggregation of Revenues and Concentration Risk [Text Block] + References No definition available. + Details
Name: | OCX_DisaggregationOfRevenuesAndConcentrationRiskTextBlock
Namespace Prefix: | OCX_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | OCX_DisclosureDisaggregationOfRevenuesAndConcentrationRiskAbstract
Namespace Prefix: | OCX_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration